1. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
- Author
-
Chong PP, Teiber D, Prokesch BC, Arasaratnam RJ, Peltz M, Drazner MH, and Garg S
- Subjects
- Acetates pharmacology, Antiviral Agents pharmacology, Cytomegalovirus drug effects, Cytomegalovirus Infections prevention & control, Cytomegalovirus Infections virology, Ganciclovir pharmacology, Ganciclovir therapeutic use, Humans, Male, Middle Aged, Mutation, Phosphotransferases (Alcohol Group Acceptor) genetics, Quinazolines pharmacology, Secondary Prevention methods, Treatment Outcome, Acetates therapeutic use, Antiviral Agents therapeutic use, Cytomegalovirus genetics, Cytomegalovirus Infections drug therapy, Drug Resistance, Viral genetics, Heart Transplantation adverse effects, Quinazolines therapeutic use
- Abstract
Letermovir was approved by the Food and Drug Administration (FDA) in November 2017 for use in adult cytomegalovirus (CMV)-seropositive allogeneic stem cell transplant (SCT) recipients for primary prophylaxis of CMV infection and disease. We report off-label use of letermovir for secondary prophylaxis of genotype-confirmed ganciclovir-resistant cytomegalovirus (CMV) syndrome (UL 97 mutation [C603W]) in a heart transplant recipient initially treated with intravenous cidofovir followed by foscarnet, both discontinued due to unacceptable toxicities., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF